Filing Flows › Companies › Jazz Pharmaceuticals › Timeline
Jazz Pharmaceuticals stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+75.1% to $234.76
Jazz Pharmaceuticals (JAZZ) stock rose 75% over the last 252 sessions, to $234.76. On the way it reported 4 quarters, its insiders filed 17 open-market trades and 25 Form 144 notices of planned sales, and the company filed 5 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 6, 2026 | Form 144 | Form 144: Bruce Cozadd plans to sell $16.2M | +3.2% (+2.9% vs SPY) | — | — |
| Nov 4, 2026 | Form 144 | Form 144: Patricia Carr plans to sell $327K | +2.1% (+0.5% vs SPY) | — | — |
| Nov 4, 2026 | Insider sale | Carr Patricia sold $289K | +2.1% (+0.5% vs SPY) | — | — |
| Nov 3, 2026 | Form 144 | Form 144: Renee D Gala plans to sell $225K | +6.9% (+6.6% vs SPY) | — | — |
| Nov 2, 2026 | Earnings | Earnings: missed the EPS estimate by -63.4% | −0.7% (−0.2% vs SPY) | +8.3% (+11.1% vs SPY) | — |
| Nov 2, 2026 | Form 144 | Form 144: Bruce Cozadd plans to sell $1.3M | −0.7% (−0.2% vs SPY) | +8.3% (+11.1% vs SPY) | — |
| Oct 9, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.8% (−2.4% vs SPY) | −3.7% (−3.4% vs SPY) | +5.4% (+10.5% vs SPY) |
| Oct 8, 2026 | Form 144 | Form 144: Anne O'Riordan plans to sell $3.4M | −3.8% (−3.4% vs SPY) | −9.8% (−8.8% vs SPY) | −1.7% (+4.2% vs SPY) |
| Oct 6, 2026 | Form 144 | Form 144: Renee D Gala plans to sell $473K | −2.0% (−2.5% vs SPY) | −8.5% (−9.0% vs SPY) | −2.7% (0.0% vs SPY) |
| Oct 1, 2026 | Form 144 | Form 144: Bruce Cozadd plans to sell $1.4M | +0.6% (+0.5% vs SPY) | −0.1% (−2.0% vs SPY) | −10.8% (−11.7% vs SPY) |
| Sep 23, 2026 | 8-K | Material definitive agreement | +0.6% (+0.7% vs SPY) | −1.4% (−0.8% vs SPY) | −9.0% (−8.5% vs SPY) |
| Sep 10, 2026 | Form 144 | Form 144: Neena Patil plans to sell $289K | −0.3% (+0.3% vs SPY) | +1.0% (+2.0% vs SPY) | −8.1% (−9.9% vs SPY) |
| Sep 8, 2026 | Form 144 | Form 144: Renee D Gala plans to sell $486K | −2.8% (−2.2% vs SPY) | −0.4% (+0.9% vs SPY) | −6.4% (−7.8% vs SPY) |
| Sep 8, 2026 | Form 144 | Form 144: Henderson, Mary Elizabeth plans to sell $664K | −2.8% (−2.2% vs SPY) | −0.4% (+0.9% vs SPY) | −6.4% (−7.8% vs SPY) |
| Sep 1, 2026 | Form 144 | Form 144: Bruce Cozadd plans to sell $1.5M | −2.8% (−2.1% vs SPY) | −4.3% (−4.2% vs SPY) | −7.9% (−7.6% vs SPY) |
| Aug 31, 2026 | 8-K | Material definitive agreement | −2.8% (−2.1% vs SPY) | −4.3% (−4.2% vs SPY) | −7.9% (−7.6% vs SPY) |
| Aug 31, 2026 | Form 144 | Form 144: Norbert G Riedel plans to sell $858K | +2.5% (+2.8% vs SPY) | +0.9% (+0.8% vs SPY) | −5.1% (−4.7% vs SPY) |
| Aug 31, 2026 | Form 144 | Form 144: Ted W Love plans to sell $373K | +2.5% (+2.8% vs SPY) | +0.9% (+0.8% vs SPY) | −5.1% (−4.7% vs SPY) |
| Aug 31, 2026 | Form 144 | Form 144: Cozadd Bruce C. plans to sell $613K | +2.5% (+2.8% vs SPY) | +0.9% (+0.8% vs SPY) | −5.1% (−4.7% vs SPY) |
| Aug 31, 2026 | Form 144 | Form 144: Patrick G Enright plans to sell $858K | +2.5% (+2.8% vs SPY) | +0.9% (+0.8% vs SPY) | −5.1% (−4.7% vs SPY) |
| Aug 31, 2026 | Form 144 | Form 144: Rick E Winningham plans to sell $858K | +2.5% (+2.8% vs SPY) | +0.9% (+0.8% vs SPY) | −5.1% (−4.7% vs SPY) |
| Aug 31, 2026 | Form 144 | Form 144: Heather Ann McSharry plans to sell $858K | +2.5% (+2.8% vs SPY) | +0.9% (+0.8% vs SPY) | −5.1% (−4.7% vs SPY) |
| Aug 31, 2026 | Form 144 | Form 144: Laura Hamill plans to sell $858K | +2.5% (+2.8% vs SPY) | +0.9% (+0.8% vs SPY) | −5.1% (−4.7% vs SPY) |
| Aug 31, 2026 | Form 144 | Form 144: Jennifer E. Cook plans to sell $858K | +2.5% (+2.8% vs SPY) | +0.9% (+0.8% vs SPY) | −5.1% (−4.7% vs SPY) |
| Aug 31, 2026 | Form 144 | Form 144: Mark Douglas Smith plans to sell $858K | +2.5% (+2.8% vs SPY) | +0.9% (+0.8% vs SPY) | −5.1% (−4.7% vs SPY) |
| Aug 31, 2026 | Form 144 | Form 144: Mary Elizabeth Henderson plans to sell $942K | +2.5% (+2.8% vs SPY) | +0.9% (+0.8% vs SPY) | −5.1% (−4.7% vs SPY) |
| Aug 31, 2026 | Form 144 | Form 144: Patrick Kennedy plans to sell $858K | +2.5% (+2.8% vs SPY) | +0.9% (+0.8% vs SPY) | −5.1% (−4.7% vs SPY) |
| Aug 27, 2026 | Form 144 | Form 144: Robert Iannone plans to sell $19.2M | +0.7% (+0.1% vs SPY) | −1.5% (−1.4% vs SPY) | −4.7% (−5.6% vs SPY) |
| Aug 10, 2026 | 8-K | Material definitive agreement | −3.4% (−3.1% vs SPY) | −3.2% (−3.2% vs SPY) | −6.1% (−4.7% vs SPY) |
| Aug 7, 2026 | Form 144 | Form 144: Anne ORiordan plans to sell $882K | 0.0% (−0.6% vs SPY) | −4.3% (−5.5% vs SPY) | −3.9% (−4.1% vs SPY) |
| Aug 3, 2026 | Earnings | Earnings: missed the EPS estimate by -7.5% | −0.5% (−1.9% vs SPY) | +1.4% (−2.0% vs SPY) | −0.9% (−3.5% vs SPY) |
| Aug 3, 2026 | Form 144 | Form 144: Bruce Cozadd plans to sell $1.5M | −0.5% (−1.9% vs SPY) | +1.4% (−2.0% vs SPY) | −0.9% (−3.5% vs SPY) |
| May 29, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.6% (−1.9% vs SPY) | +0.9% (+3.4% vs SPY) | +1.9% (+2.9% vs SPY) |
| May 28, 2026 | Insider sale | Pearce Samantha sold $1.6M | −0.9% (−1.5% vs SPY) | −2.8% (−3.3% vs SPY) | −3.2% (−0.6% vs SPY) |
| May 22, 2026 | Insider sale | Winningham Rick E sold $662K | +0.2% (−0.2% vs SPY) | −1.2% (−3.0% vs SPY) | −3.9% (−2.9% vs SPY) |
| May 22, 2026 | Insider sale | McSharry Heather Ann sold $482K | +0.2% (−0.2% vs SPY) | −1.2% (−3.0% vs SPY) | −3.9% (−2.9% vs SPY) |
| May 5, 2026 | Earnings | Earnings: beat the EPS estimate by 36.2% | +2.0% (+1.2% vs SPY) | +7.2% (+4.3% vs SPY) | +10.4% (+5.5% vs SPY) |
| Mar 9, 2026 | Insider sale | Carr Patricia sold $235K | +1.8% (+1.0% vs SPY) | −1.9% (−0.4% vs SPY) | +4.8% (+6.5% vs SPY) |
| Feb 27, 2026 | Insider sale | Riedel Norbert G sold $656K | +0.6% (+1.0% vs SPY) | −2.9% (−1.7% vs SPY) | −3.4% (+4.7% vs SPY) |
| Feb 27, 2026 | Insider sale | Carr Patricia sold $213K | +0.6% (+1.0% vs SPY) | −2.9% (−1.7% vs SPY) | −3.4% (+4.7% vs SPY) |
| Feb 26, 2026 | Insider sale | Patil Neena M sold $10.7M | −4.1% (−3.5% vs SPY) | −4.2% (−3.1% vs SPY) | −4.0% (+3.0% vs SPY) |
| Feb 26, 2026 | Insider sale | Henderson Mary Elizabeth sold $1.0M | −4.1% (−3.5% vs SPY) | −4.2% (−3.1% vs SPY) | −4.0% (+3.0% vs SPY) |
| Feb 26, 2026 | Insider sale | Carr Patricia sold $243K | −4.1% (−3.5% vs SPY) | −4.2% (−3.1% vs SPY) | −4.0% (+3.0% vs SPY) |
| Feb 24, 2026 | Earnings | Earnings: beat the EPS estimate by 11.0% | +0.3% (−0.4% vs SPY) | +9.5% (+8.9% vs SPY) | +6.6% (+10.7% vs SPY) |
| Dec 9, 2025 | Insider sale | Henderson Mary Elizabeth sold $379K | −4.0% (−3.9% vs SPY) | +0.3% (+0.8% vs SPY) | −5.3% (−6.4% vs SPY) |
| Dec 5, 2025 | Insider sale | Carr Patricia sold $798K | +1.7% (+1.5% vs SPY) | −1.2% (−1.9% vs SPY) | 0.0% (−1.3% vs SPY) |
| Nov 26, 2025 | Insider sale | Cozadd Bruce C sold $13.8M | −1.8% (−2.4% vs SPY) | −7.5% (−8.8% vs SPY) | −5.5% (−8.0% vs SPY) |
| Nov 20, 2025 | Insider sale | McSharry Heather Ann sold $607K | −0.2% (+1.4% vs SPY) | +0.5% (−2.1% vs SPY) | −5.3% (−8.3% vs SPY) |
| Nov 18, 2025 | Insider sale | Winningham Rick E sold $995K | +5.9% (+6.8% vs SPY) | +6.2% (+5.7% vs SPY) | −3.1% (−3.9% vs SPY) |
| Nov 18, 2025 | Insider sale | Carr Patricia sold $968K | +5.9% (+6.8% vs SPY) | +6.2% (+5.7% vs SPY) | −3.1% (−3.9% vs SPY) |
| Nov 18, 2025 | Insider sale | Cozadd Bruce C sold $3.3M | +5.9% (+6.8% vs SPY) | +6.2% (+5.7% vs SPY) | −3.1% (−3.9% vs SPY) |
Insiders’ record here
In the year on the chart, Jazz Pharmaceuticals' insiders reported 0 open-market buys ($0) and 17 sales ($36.9M). Of the 16 old enough to score, 4 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale +10.8%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Jazz Pharmaceuticals: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.